Literature DB >> 8107232

Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity.

X Y Ma1, P Sova, W Chao, D J Volsky.   

Abstract

The infectivity factor of human immunodeficiency virus type 1 (HIV-1), Vif, contains two cysteine residues which are highly conserved among animal lentiviruses. We introduced substitutions of leucine for cysteine residues in the vif gene of a full-length HIV-1 clone to analyze their roles in viral infection. Mutant viruses containing substitutions in either Cys-114, Cys-133, or both displayed a vif-negative infection phenotype similar to that of an isogeneic vif deletion mutant, namely, a cell-dependent complete to partial loss of infectivity. The vif defect could be complemented by cotransfection of mutant viral DNA with a Vif expression vector, and there was no evidence that recombination contributed to the repair of the vif deficiency. The viral protein profile, as determined by immunoblotting, in cells infected with cysteine substitution mutants and that in wild-type virus were similar, including the presence of the 23-kDa Vif polypeptide. In addition, immunoblotting with an antiserum directed against the carboxyl terminus of gp41 revealed that gp41 was intact in cells infected with either wild-type or vif mutant HIV-1, excluding that Vif cleaves the C terminus of gp41. Our results indicate that the cysteines in HIV-1 Vif are critical for Vif function in viral infectivity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107232      PMCID: PMC236631     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

Authors:  J Sodroski; W C Goh; C Rosen; A Tartar; D Portetelle; A Burny; W Haseltine
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

4.  The HIV 'A' (sor) gene product is essential for virus infectivity.

Authors:  K Strebel; D Daugherty; K Clouse; D Cohen; T Folks; M A Martin
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

7.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

8.  Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera.

Authors:  N C Kan; G Franchini; F Wong-Staal; G C DuBois; W G Robey; J A Lautenberger; T S Papas
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses.

Authors:  L Chakrabarti; M Guyader; M Alizon; M D Daniel; R C Desrosiers; P Tiollais; P Sonigo
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

View more
  29 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

Review 4.  Lentiviral Vif: viral hijacker of the ubiquitin-proteasome system.

Authors:  Elana S Ehrlich; Xiao-Fang Yu
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

5.  Sequence analysis of HIV-1 vif gene in Spanish isolates.

Authors:  I Olivares; L Menéndez-Arias; A Rodríguez-Bernabé; M J Martin; J Dopazo; C López-Galíndez
Journal:  Virus Genes       Date:  1995-02       Impact factor: 2.332

Review 6.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

7.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.

Authors:  Yunkai Yu; Zuoxiang Xiao; Elana S Ehrlich; Xianghui Yu; Xiao-Fang Yu
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

9.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.

Authors:  Sandrina Dafonseca; Pascale Coric; Bernard Gay; Saw See Hong; Serge Bouaziz; Pierre Boulanger
Journal:  Virol J       Date:  2008-12-23       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.